Vaxcyte Finalizes $600.2M Public Offering with Full Over-Allotment Exercise

summarizeSummary

Vaxcyte, Inc. announced the finalization of its public offering, including the full exercise of the underwriters' option, resulting in total net proceeds of approximately $600.2 million.

check_boxKey Events

• Offering Finalized and Closed

  Vaxcyte, Inc. completed its public offering on February 2, 2026, selling 11,000,000 shares of common stock at $50.00 per share.

• Over-Allotment Option Fully Exercised

  Underwriters notified Vaxcyte on January 30, 2026, of their intent to fully exercise their option to purchase an additional 1,650,000 shares.

• Significant Capital Infusion

  The total offering, including the over-allotment, generated approximately $600.2 million in net proceeds for the company, substantially strengthening its financial position.

auto_awesomeAnalysis

This 8-K filing provides the definitive details of Vaxcyte's public offering, confirming the full exercise of the underwriters' over-allotment option. This brings the total capital raised to approximately $600.2 million, a substantial increase from the initial offering size. The successful completion of this significant financing event, including the strong demand evidenced by the full option exercise, provides Vaxcyte with considerable funding to advance its clinical-stage vaccine pipeline and operations. This filing follows the preliminary prospectus on January 29, 2026, and the initial finalization reported on January 30, 2026, adding the crucial detail of the over-allotment exercise.